Market Intelligence, Clinical Progress, and High-Purity Reagents for DNA Damage Response (DDR) Therapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for DNA-PKcs/PRKDC drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | DNA-PKcs (PRKDC) Recombinant Protein / Specific Domains High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View PRKDC Products |
| Gene Delivery | PRKDC Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View PRKDC Products |
| Benchmark Ab | Anti-DNA-PKcs (Nedisertib/M3814 Sequence) Recombinant positive control. |
View PRKDC Products |
| Validator | PRKDC siRNA Set For knockdown verification. |
View PRKDC Products |
| Related Target A | ATM Master regulator of double-strand break repair, crucial for selectivity screening. |
View ATM Products |
| Related Target B | ATR Key DDR kinase coordinating replication stress, evaluated in combo or selectivity screens. |
View ATR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Mass-spectrometry grade purity for structural/selectivity assays | High purity (>95%) recombinant kinase domains and binding partners (Ku70/Ku80) |
| Off-target kinase screening (PIKK family selectivity) | ATM, ATR, and mTOR homolog protein panels strictly verified by mass spec |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live DNA-PKcs/PRKDC R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for DNA-PKcs/PRKDC therapeutics is intensifying, with major players shifting focus from traditional monotherapies to combination regimens with radiotherapy, chemotherapy, and immune checkpoint inhibitors. As first-generation therapies reach the clinic, the next wave of R&D is targeting highly selective small molecule inhibitors to overcome off-target toxicities associated with other PIKK family members.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule | Merck KGaA (Nedisertib), AstraZeneca (AZD7648) | Solid Tumors, CLL, Glioblastoma | Selectivity Assay (Need Mutant vs WT Proteins) |
| siRNA/Gene Therapy | Academic/Biotech Consortiums | Sensitizing Resistant Cancers | Target Knockdown Validation (Need siRNA Set & Lentivirus) |